Prevalence of anxiety and depression in people with different types of cancer or haematologic malignancies: a cross-sectional study.
Cancer
mental disorders
oncology
psycho-oncology
Journal
Epidemiology and psychiatric sciences
ISSN: 2045-7979
Titre abrégé: Epidemiol Psychiatr Sci
Pays: England
ID NLM: 101561091
Informations de publication
Date de publication:
17 Oct 2022
17 Oct 2022
Historique:
entrez:
17
10
2022
pubmed:
18
10
2022
medline:
19
10
2022
Statut:
epublish
Résumé
Cancer patients often present with psychological symptoms that affect their quality of life, physical health outcomes and survival. Two of the most frequent psychiatric comorbidities are anxiety and depression. However, the prevalence of these disorders among cancer patients remains unclear, as studies frequently report varying rates. In the present study, we aimed to provide robust point estimates for the prevalence of anxiety and depression for both a mixed cancer sample and for 13 cancer types separately, considering confounding variables. In a sample of 7509 cancer outpatients (51.4% female), we used the About one third of our sample showed symptoms of anxiety (35.2%) or depression (27.9%), and every sixth patient had a very likely psychiatric condition, with women being more frequently affected. Elderly patients more often showed signs of depression. The prevalence of anxiety and depression was significantly higher in lung and brain cancer patients, than in other cancer patients. Lowest depression rates were found in breast cancer patients. The prevalence of anxiety and depression is high in cancer patients. Type of cancer is an important predictor for anxiety and depressive symptoms, with lung and brain cancer patients being highly burdened. Considering a personalised medicine approach, physicians should take into account the high prevalence of psychiatric comorbidities and include psychiatric consultations in the treatment plan.
Identifiants
pubmed: 36245424
doi: 10.1017/S2045796022000592
pii: S2045796022000592
pmc: PMC9583630
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e74Références
Eur J Cancer Care (Engl). 2019 May;28(3):e13086
pubmed: 31087398
Psychol Med. 2014 Aug;44(11):2363-74
pubmed: 24451993
Psychol Med. 2004 May;34(4):597-611
pubmed: 15099415
J Affect Disord. 2012 Dec 10;141(2-3):343-51
pubmed: 22727334
Cancer Med. 2022 Sep;11(18):3387-3396
pubmed: 35315594
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Support Care Cancer. 2014 Feb;22(2):453-9
pubmed: 24091720
Health Qual Life Outcomes. 2003 Aug 01;1:29
pubmed: 12914662
Psychooncology. 2021 Mar;30(3):312-320
pubmed: 33089560
Support Care Cancer. 2019 Jan;27(1):57-67
pubmed: 30225571
J Affect Disord. 2011 Jun;131(1-3):1-7
pubmed: 20732716
Lancet Psychiatry. 2014 Oct;1(5):343-50
pubmed: 26360998
Psychooncology. 2019 Dec;28(12):2382-2388
pubmed: 31679172
J Natl Cancer Inst Monogr. 2004;(32):57-71
pubmed: 15263042
Breast Cancer Res Treat. 2019 Aug;176(3):519-533
pubmed: 31087199
Int J Environ Res Public Health. 2019 Jan 31;16(3):
pubmed: 30709020
Int J Clin Health Psychol. 2022 Sep-Dec;22(3):100315
pubmed: 35662789
Onco Targets Ther. 2016 Feb 29;9:1023-8
pubmed: 27013895
Int J Cancer. 2022 Jul 1;151(1):77-82
pubmed: 35128650
Psychooncology. 2021 Apr;30(4):504-510
pubmed: 33210393
Acta Oncol. 2017 Feb;56(2):146-155
pubmed: 28140731
Asian Pac J Cancer Prev. 2018 Jun 25;19(6):1661-1669
pubmed: 29938451
Psychooncology. 2014 Feb;23(2):121-30
pubmed: 24105788
BMJ. 2018 Apr 25;361:k1415
pubmed: 29695476
Front Psychol. 2021 Apr 15;12:585534
pubmed: 33935849
Cancer. 2019 Oct 1;125(19):3418-3427
pubmed: 31246284
BMC Cancer. 2019 Oct 11;19(1):943
pubmed: 31604468
Eur J Cancer. 2021 Oct;156:24-34
pubmed: 34411849